MIB-1 immunoreactivity correlates with blood vessel density and survival in disseminated malignant melanoma.
The purpose of our current work was to evaluate the prognostic significance of tumor cell proliferation in advanced metastatic melanomas and to investigate a possible correlation between the proliferation index and blood vessel density in metastatic tissue. Sixty patients with disseminated malignant melanoma treated with four-drug chemotherapy combined with interferon-alpha were included in this study. Proliferative activity and vascularity in metastatic tissues were examined by immunohistochemistry with anti-Ki-67 (MIB-1) and anti-CD31 antibody, respectively. A significant relationship between MIB-1 index and blood vessel number was detected (rho = 0.323, p = 0.013). In survival analysis, the overall survival and disease-free survival were significantly longer (58 and 38 vs. 38 and 17 months) for patients with low MIB-1 immunoreactivity (p = 0.012 and p = 0.023, respectively). Likewise, the low MIB-1 labeling index was associated with the prolonged survival calculated from the initiation of the chemoimmunotherapy (12 vs. 7 months, p = 0.032). In multivariate Cox's proportional hazard analysis, MIB-1 positivity was an independent prognostic factor both for overall survival and for survival after beginning of the chemoimmunotherapy (p = 0.016 and p = 0.029).
Vlaykova
T
T
Department of Oncology, Turku University Central Hospital, Turku, Finland.
Talve
L
L
Hahka-Kemppinen
M
M
Hernberg
M
M
Muhonen
T
T
Franssila
K
K
Collan
Y
Y
Pyrhönen
S
S
D000328:Adult; D000368:Aged; D034961:Antigens, Nuclear; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001324:Autoantigens / Q000276:immunology*; D014408:Biomarkers, Tumor / Q000276:immunology*; D018572:Disease-Free Survival; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007167:Immunotherapy; D019394:Ki-67 Antigen; D008297:Male; D008545:Melanoma / Q000098:blood supply* / Q000276:immunology* / Q000556:secondary / Q000628:therapy; D008875:Middle Aged; D009687:Nuclear Proteins / Q000276:immunology*; D011379:Prognosis; D016016:Proportional Hazards Models; D012878:Skin Neoplasms / Q000098:blood supply* / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D016019:Survival Analysis
D034961:Antigens, Nuclear; D000970:Antineoplastic Agents; D001324:Autoantigens; D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D009687:Nuclear Proteins